Boston Scientific Corp. (NYSE:BSX) enrolled the 630th and final patient in its MAPS clinical trial comparing treatment of brain aneurysms with bare-metal and biopolymer-coated coils.
The study, which the Natick, Mass.-based medical device giant began in 2007, aims to measure how often aneurysms recur one year after being treated with its bare-platinum GDC and biopolymer-coated Matrix2 detachable coils.
Boston Scientific said the Maps trial, being conducted in 47 hospitals in 11 countries, will also compare “secondary angiographic endpoints” with “the primary clinical outcomes over several years to evaluate the long-term predictive value of 12-month angiography.” Results are expected to be published in 2011, according to a press release.
In May, BSX released five-year data from its ISAT trial showing that patients treated with endovascular coil embolization for ruptured intracranial aneurysms are 23 percent less likely to die within five years, compared with patients treated by surgical clipping of the aneurysm.
And in August, Neurosurgery magazine published a study evaluating the risks of re-treating brain aneurysms after endovascular coil embolization in 311 cases. That study, which looked at data from coil embolizations using devices made by Boston Scientific and Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp., indicated that the risk of death or permanent major disability was 1.28 percent, or just more than one in 100.